Clinical Trial Update: Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial [Phase 3]

View source ↗

Summary

Phase 3 RECIPROCAL trial examines different dosing schedules of Lutetium-177 Lu-PSMA radioligand therapy in advanced prostate cancer; the study is not yet recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Pluvicto (lutetium-177 PSMA-617)

Snippet

Sponsor: Alliance for Clinical Trials in Oncology | Conditions: Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 3 | Status: NOT_YET_RECRUITING